22nd Century to Speak at Global Tobacco & Nicotine Forum
September 13 2017 - 9:55AM
Business Wire
22nd Century Group, Inc. (NYSE American:XXII), a plant
biotechnology company that is focused on tobacco harm reduction,
announced today that officials from the Global Tobacco &
Nicotine Forum (GTNF) have invited the Company’s Chief Executive
Officer, Henry Sicignano, III, to participate on a GTNF panel
entitled “Future Next Generation Products” on September 14, 2017 in
New York City.
The Global Tobacco & Nicotine Forum is the world’s foremost
exchange of ideas and information for tobacco technologies and
products. Attendees to the forum include public health advocates,
policymakers, scientists, and international tobacco industry
executives. Visit www.gtnf-2017.com for more on GTNF. Also speaking
at this year’s forum are:
Mitch Zeller, Director, US Food and Drug
Administration’s Center for Tobacco Products. Together with FDA
Commissioner, Dr. Scott Gottlieb, in August 2017, Mr. Zeller,
released an article entitled, “A Nicotine-Focused Framework of
Public Health.” Published in The New England Journal of Medicine
(NEJM), the article spells out the FDA’s regulatory authority for
mandating non-addictive levels of nicotine in combustible
cigarettes.
Dr. Dorothy Hatsukami, Forster Family Chair
in Cancer Prevention; Associate Director, Masonic Cancer Center;
and Professor of Psychiatry, University of Minnesota. In 2016,
together with two other prominent scientists, Dr. Dorothy Hatsukami
wrote in Tobacco Control that failure to act on the World Health
Organization (WHO) recommendation of mandating nicotine reductions
in cigarettes to non-addictive levels could lead to the loss of
millions of lives.
Dr. Michael Cummings, Professor, Medical
University of South Carolina Department of Psychiatry &
Behavioral Sciences; and Co-Director, Tobacco Policy and Control
Program at Hollings Cancer Center. As an expert in tobacco policy,
Dr. Cummings is often called upon to guide global tobacco control
policy initiatives around the world. Earlier in 2017, Dr. Cummings
gave the keynote address at 22nd Century’s Annual Meeting of
Stockholders.
“Since the FDA announced its intention to mandate that all
cigarettes have very low, non-addictive levels of nicotine, the
public health community has focused much of its attention on 22nd
Century,” explained Henry Sicignano, III, President and Chief
Executive Officer of 22nd Century Group. “We look forward to
working together with scientists and policymakers to make Very Low
Nicotine cigarettes a public health reality in the United States
and around the world.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on genetic
engineering and plant breeding which allows the increase or
decrease of the level of nicotine in tobacco plants and the level
of cannabinoids in cannabis plants. The Company’s primary mission
in tobacco is to reduce the harm caused by smoking. The Company’s
primary mission in cannabis is to develop proprietary hemp/cannabis
strains for important new medicines and agricultural crops. Visit
www.xxiicentury.com and www.botanicalgenetics.com for more
information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2016, filed on March 8, 2017,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913005828/en/
22nd Century GroupJames Vail, 716-270-1523Director of
Communicationsjvail@xxiicentury.com
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2024 to May 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From May 2023 to May 2024